BMEA

Michael J.M. Hitchcock

Known title: DirectorCIK: 0001856674

Michael J.M. Hitchcock's purchase track record

How the stock did after each of Michael J.M. Hitchcock's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
3
of 3 since November 14, 2022
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+43.2%
3 months: +31.7%
Beat the S&P 500
67%
median +31.7% vs. index
PurchaseStockAmount3 months6 months
12/2/2025BMEA$99K+39.0%+43.2%
9/30/2024BMEA$101K-61.6%-78.9%
11/14/2022BMEA$40K+31.7%+326.1%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 29, 2026

Biomea Fusion Cancels Equity Offering, Shares Drop 19%. Biomea Fusion announced the termination of its proposed public equity offering, citing market conditions. The cancellation removes expected dilution relief and leaves the company with near‑term runway pressure. Following the news, the stock fell about 19% in after‑hours trading. The development occurs amid broader health‑care stock activity.

this person other insiders at BMEA

Transaction History

BMEA▲ Buy$99K
BMEA▲ Buy$101K
BMEA▲ Buy$40K

We use analytics to understand how market-wall is used. No personal data is sold.